Robert Lechleider insider trades: Immunome (IMNM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | IMNM | ↓ Sell | 55,000 | $22.62 | $1.2M | Direct | Jul 7, 2026 (5d) |
| Jun 25, 2026 | IMNM | ↓ Sell | 55,000 | $19.85 | $1.1M | Direct | Jun 29, 2026 (4d) |
| Nov 21, 2024 | IMNM | ↑ Buy | 15,805 | $9.48 | $150K | Direct | Nov 25, 2024 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMNM insiders
Open-market trades in the last 12 months
About Robert Lechleider's insider trades
Robert Lechleider is Chief Medical Officer at Immunome (IMNM). Since Nov 21, 2024, Robert has reported 1 open-market purchase worth $150K and 2 sales worth $2.3M on SEC Form 4. In the last 12 months: 2 sales ($2.3M).
Their filings also include grants and awards (3 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.